Non-invasive Systemic Drug Delivery: Developability Considerations for Alternate Routes of Administration
- 1 January 2010
- journal article
- review article
- Published by Elsevier BV in Journal of Pharmaceutical Sciences
- Vol. 99 (1), 1-20
- https://doi.org/10.1002/jps.21793
Abstract
No abstract availableThis publication has 80 references indexed in Scilit:
- Prediction of human oral pharmacokinetics using nonclinical data: examples involving four proprietary compoundsBiopharmaceutics & Drug Disposition, 2008
- The Economics of Drug Discovery and the Ultimate Valuation of Pharmacotherapies in the MarketplaceClinical Pharmacology & Therapeutics, 2008
- Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administrationInternational Journal of Pharmaceutics, 2008
- A Novel Strategy for Physiologically Based Predictions of Human PharmacokineticsClinical Pharmacokinetics, 2006
- Can the pharmaceutical industry reduce attrition rates?Nature Reviews Drug Discovery, 2004
- Role of the Development Scientist in Compound Lead Selection and OptimizationJournal of Pharmaceutical Sciences, 2000
- Randomized Comparative Trial of Nicotine Polacrilex, a Transdermal Patch, Nasal Spray, and an InhalerArchives of Internal Medicine, 1999
- Effects of physicochemical properties and other factors on systemic nasal drug deliveryAdvanced Drug Delivery Reviews, 1998
- Biopharmaceutical evaluation of transnasal, sublingual, and buccal disk dosage forms of butorphanolBiopharmaceutics & Drug Disposition, 1993
- Bioavailability of Leuprolide Acetate Following Nasal and Inhalation Delivery to Rats and Healthy HumansPharmaceutical Research, 1992